Italian guidelines for therapy of atopic dermatitis—Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis)

“Skin Allergy” Group of SIDeMaST, “ADOI” (Associazione Dermatologi Ospedalieri Italiani), “SIDAPA” (Società Italiana di Dermatologia Allergologica, Professionale e Ambientale)

Research output: Contribution to journalArticle

Abstract

Atopic dermatitis (AD) therapeutic approach calls for a long-term treatment. Treatment options for AD have recently undergone a revolutionary change by the introduction of the first biologic drug. Availability in daily practice of the last version of international AD guidelines, taking peculiarities of the country into account, can contribute to good clinical practice in Italy. To adapt European Dermatology Forum (EDF) guidelines for AD to the Italian medical–legal context, the EDF guidelines were assessed independently by two independent Italian renowned experts in the field and further integrated with articles published and systematically reviewed before May 2019. The first draft was collegially corrected and updated by the members of the SIDEMAST, ADOI, and SIDAPA. Recommendation levels (A; B; C; D) were graded based on the evidence levels (1–4). The adapted guidelines presented here focus on topical and systemic therapies in AD patients, both children and adults. As opposed to previous Italian guidelines, they include indications about biologics. New relevant evidence available from very recent literature and peculiarities of the Italian medical and legal context have been integrated in the revision process. If compared to general guidelines for AD not adapted to a specific national and cultural context, a revision for specific Italian needs is now available: It comprises the option of implementing the new biologic treatments and is likely to provide an important contribution to the improvement of clinical practice in Italy. Cooperation between patients, dermatologists, allergologists, and pediatricians remains mandatory in AD management. The authors of the present revision recommend an update of the Italian guidelines to be performed at least every second year.

Original languageEnglish
Article numbere13121
JournalDermatologic Therapy
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Atopic Dermatitis
Guidelines
Dermatology
Italy
Therapeutics
Patient Compliance
Biological Products
Pharmaceutical Preparations

Keywords

  • atopic dermatitis
  • atopic eczema
  • azatioprin
  • cyclosporin
  • dupilumab
  • methotrexate
  • phototherapy
  • topicals

ASJC Scopus subject areas

  • Dermatology

Cite this

“Skin Allergy” Group of SIDeMaST, “ADOI” (Associazione Dermatologi Ospedalieri Italiani), & “SIDAPA” (Società Italiana di Dermatologia Allergologica, Professionale e Ambientale) (Accepted/In press). Italian guidelines for therapy of atopic dermatitis—Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). Dermatologic Therapy, [e13121]. https://doi.org/10.1111/dth.13121

Italian guidelines for therapy of atopic dermatitis—Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). / “Skin Allergy” Group of SIDeMaST; “ADOI” (Associazione Dermatologi Ospedalieri Italiani); “SIDAPA” (Società Italiana di Dermatologia Allergologica, Professionale e Ambientale).

In: Dermatologic Therapy, 01.01.2019.

Research output: Contribution to journalArticle

“Skin Allergy” Group of SIDeMaST, “ADOI” (Associazione Dermatologi Ospedalieri Italiani) & “SIDAPA” (Società Italiana di Dermatologia Allergologica, Professionale e Ambientale) 2019, 'Italian guidelines for therapy of atopic dermatitis—Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis)', Dermatologic Therapy. https://doi.org/10.1111/dth.13121
“Skin Allergy” Group of SIDeMaST, “ADOI” (Associazione Dermatologi Ospedalieri Italiani), “SIDAPA” (Società Italiana di Dermatologia Allergologica, Professionale e Ambientale). Italian guidelines for therapy of atopic dermatitis—Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). Dermatologic Therapy. 2019 Jan 1. e13121. https://doi.org/10.1111/dth.13121
“Skin Allergy” Group of SIDeMaST ; “ADOI” (Associazione Dermatologi Ospedalieri Italiani) ; “SIDAPA” (Società Italiana di Dermatologia Allergologica, Professionale e Ambientale). / Italian guidelines for therapy of atopic dermatitis—Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). In: Dermatologic Therapy. 2019.
@article{fed8513be4f140ac827beff2ce58716e,
title = "Italian guidelines for therapy of atopic dermatitis—Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis)",
abstract = "Atopic dermatitis (AD) therapeutic approach calls for a long-term treatment. Treatment options for AD have recently undergone a revolutionary change by the introduction of the first biologic drug. Availability in daily practice of the last version of international AD guidelines, taking peculiarities of the country into account, can contribute to good clinical practice in Italy. To adapt European Dermatology Forum (EDF) guidelines for AD to the Italian medical–legal context, the EDF guidelines were assessed independently by two independent Italian renowned experts in the field and further integrated with articles published and systematically reviewed before May 2019. The first draft was collegially corrected and updated by the members of the SIDEMAST, ADOI, and SIDAPA. Recommendation levels (A; B; C; D) were graded based on the evidence levels (1–4). The adapted guidelines presented here focus on topical and systemic therapies in AD patients, both children and adults. As opposed to previous Italian guidelines, they include indications about biologics. New relevant evidence available from very recent literature and peculiarities of the Italian medical and legal context have been integrated in the revision process. If compared to general guidelines for AD not adapted to a specific national and cultural context, a revision for specific Italian needs is now available: It comprises the option of implementing the new biologic treatments and is likely to provide an important contribution to the improvement of clinical practice in Italy. Cooperation between patients, dermatologists, allergologists, and pediatricians remains mandatory in AD management. The authors of the present revision recommend an update of the Italian guidelines to be performed at least every second year.",
keywords = "atopic dermatitis, atopic eczema, azatioprin, cyclosporin, dupilumab, methotrexate, phototherapy, topicals",
author = "{“Skin Allergy” Group of SIDeMaST} and {“ADOI” (Associazione Dermatologi Ospedalieri Italiani)} and {“SIDAPA” (Societ{\`a} Italiana di Dermatologia Allergologica, Professionale e Ambientale)} and Giovanni Damiani and Piergiacomo Calzavara-Pinton and Luca Stingeni and Katharina Hansel and Francesco Cusano and Pigatto, {Paolo D.M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/dth.13121",
language = "English",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Blackwell Publishing Inc.",

}

TY - JOUR

T1 - Italian guidelines for therapy of atopic dermatitis—Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis)

AU - “Skin Allergy” Group of SIDeMaST

AU - “ADOI” (Associazione Dermatologi Ospedalieri Italiani)

AU - “SIDAPA” (Società Italiana di Dermatologia Allergologica, Professionale e Ambientale)

AU - Damiani, Giovanni

AU - Calzavara-Pinton, Piergiacomo

AU - Stingeni, Luca

AU - Hansel, Katharina

AU - Cusano, Francesco

AU - Pigatto, Paolo D.M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Atopic dermatitis (AD) therapeutic approach calls for a long-term treatment. Treatment options for AD have recently undergone a revolutionary change by the introduction of the first biologic drug. Availability in daily practice of the last version of international AD guidelines, taking peculiarities of the country into account, can contribute to good clinical practice in Italy. To adapt European Dermatology Forum (EDF) guidelines for AD to the Italian medical–legal context, the EDF guidelines were assessed independently by two independent Italian renowned experts in the field and further integrated with articles published and systematically reviewed before May 2019. The first draft was collegially corrected and updated by the members of the SIDEMAST, ADOI, and SIDAPA. Recommendation levels (A; B; C; D) were graded based on the evidence levels (1–4). The adapted guidelines presented here focus on topical and systemic therapies in AD patients, both children and adults. As opposed to previous Italian guidelines, they include indications about biologics. New relevant evidence available from very recent literature and peculiarities of the Italian medical and legal context have been integrated in the revision process. If compared to general guidelines for AD not adapted to a specific national and cultural context, a revision for specific Italian needs is now available: It comprises the option of implementing the new biologic treatments and is likely to provide an important contribution to the improvement of clinical practice in Italy. Cooperation between patients, dermatologists, allergologists, and pediatricians remains mandatory in AD management. The authors of the present revision recommend an update of the Italian guidelines to be performed at least every second year.

AB - Atopic dermatitis (AD) therapeutic approach calls for a long-term treatment. Treatment options for AD have recently undergone a revolutionary change by the introduction of the first biologic drug. Availability in daily practice of the last version of international AD guidelines, taking peculiarities of the country into account, can contribute to good clinical practice in Italy. To adapt European Dermatology Forum (EDF) guidelines for AD to the Italian medical–legal context, the EDF guidelines were assessed independently by two independent Italian renowned experts in the field and further integrated with articles published and systematically reviewed before May 2019. The first draft was collegially corrected and updated by the members of the SIDEMAST, ADOI, and SIDAPA. Recommendation levels (A; B; C; D) were graded based on the evidence levels (1–4). The adapted guidelines presented here focus on topical and systemic therapies in AD patients, both children and adults. As opposed to previous Italian guidelines, they include indications about biologics. New relevant evidence available from very recent literature and peculiarities of the Italian medical and legal context have been integrated in the revision process. If compared to general guidelines for AD not adapted to a specific national and cultural context, a revision for specific Italian needs is now available: It comprises the option of implementing the new biologic treatments and is likely to provide an important contribution to the improvement of clinical practice in Italy. Cooperation between patients, dermatologists, allergologists, and pediatricians remains mandatory in AD management. The authors of the present revision recommend an update of the Italian guidelines to be performed at least every second year.

KW - atopic dermatitis

KW - atopic eczema

KW - azatioprin

KW - cyclosporin

KW - dupilumab

KW - methotrexate

KW - phototherapy

KW - topicals

UR - http://www.scopus.com/inward/record.url?scp=85074876593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074876593&partnerID=8YFLogxK

U2 - 10.1111/dth.13121

DO - 10.1111/dth.13121

M3 - Article

C2 - 31625221

AN - SCOPUS:85074876593

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

M1 - e13121

ER -